Biotech entity
pharma is the sole category represented across all 2 tracked stories. Acadia Pharmaceuticals is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. The 15-day window averages about 0.9 stories each week. The 5 average consequence score is below the beat benchmark of 6.1 in the same window.
Last mentioned: Mar 19, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 2 tracked stories. Acadia Pharmaceuticals is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. The 15-day window averages about 0.9 stories each week. The 5 average consequence score is below the beat benchmark of 6.1 in the same window. They are less corroborated than the beat average, carrying 2 original sources each against 3.5 for the same window. This profile follows 2 Biotech stories mentioning Zevra Therapeutics across the period from March 5, 2026 to March 19, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 219 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Zevra Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
Earnings Call
Management hosts a conference call to discuss 2025 performance and 2026 outlook.
Financial Reporting
XOMA files Q4 and Full Year 2025 financial results with the SEC.
Asset Acquisition
Completion of a significant acquisition of royalty rights from a clinical-stage partner.
Strategic Disclosure
XOMA issues Regulation FD disclosure regarding portfolio updates.
XOMA Royalty reported its Q4 and full-year 2025 financial results, highlighting a significant expansion of its royalty portfolio and the continued commercial success of key assets like Vabysmo and Daybue. The company remains focused on its strategic pivot toward becoming a pure-play royalty aggregator in the biotechnology sector.
Source: tickerreport.com · dailypolitical.com
Zevra Therapeutics has appointed Justin Renz as its new Chief Financial Officer, bringing over 20 years of biotech leadership to the rare disease specialist. The move comes as Zevra prioritizes the commercial rollout of Miplyffa, its recently FDA-approved treatment for Niemann-Pick disease type C.
Source: finanznachrichten.de · Seeking Alpha
Zevra Therapeutics is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
